

2014

USP6 Translocation in Giant Cell Granulomas of the Jaws

Nagamani Narayana

University of Nebraska Medical Center, nnarayana@unmc.edu

Tell us how you used this information in this [short survey](#).

Follow this and additional works at: https://digitalcommons.unmc.edu/cod_pres

Recommended Citation

Narayana, Nagamani, "USP6 Translocation in Giant Cell Granulomas of the Jaws" (2014). *Posters and Presentations: College of Dentistry*. 3.

https://digitalcommons.unmc.edu/cod_pres/3

This Conference Proceeding is brought to you for free and open access by the College of Dentistry at DigitalCommons@UNMC. It has been accepted for inclusion in Posters and Presentations: College of Dentistry by an authorized administrator of DigitalCommons@UNMC. For more information, please contact digitalcommons@unmc.edu.

USP6 Translocation in Giant Cell Granulomas of the Jaws

Nagamani Narayana

University of Nebraska Medical Center College of Dentistry
Lincoln, Nebraska, USA

INTRODUCTION

- Central giant cell granulomas (CGCG) account for 7% of all benign tumors of the jaw while peripheral giant cell granulomas (PGCG) occur on the gingiva (Table 1).
- The underlying pathophysiology of CGCG and PGCG is not known. Therefore there are studies attempting to identify biomarkers to increase understanding the pathogenesis of CGCG and PGCG.
- Some authors consider CGCG in jaw bones similar to giant cell tumors of long bones while others believe them to be reactive or non-neoplastic lesions.
- Recurrence of these lesions following conservative treatment is attributed to matrix metalloproteinases, namely MMP9. Recent studies have shown an increase in levels of MMP 9 in central and peripheral giant cell granulomas as in aneurysmal bone cysts (ABC).
- De-ubiquitinating enzymes play an important role in cellular processes, though their precise role in normal physiology is not fully understood. USP6 is the first de-ubiquitinating enzyme recognized as an oncogene.
- Recently studies have described the USP6 translocation in CGCG as transforming this lesion to a neoplasm. This retrospective study analyzed two cases of CGCG and one PGCG for the USP6 translocation.

MATERIALS & METHODS

Studied representative samples from two cases of recurrent CGCG and one case of recurrent PGCG cytogenetically; each case exhibited typical microscopic and radiographic features of CGCG and PGCG. The clinical data for three patients are summarized in Table 2.

Fluorescence in situ hybridization (FISH) study:

- Deparaffinized paraffin-embedded 4 μ m tissue sections in xylene, dehydrated in 100% ethanol, and treated with 100mmol/L Tris and 50mmol/L EDTA (pH7.0) for 15 minutes at 93°C.
- Rinsed tissue sections once in PBS and protein digested with Digest All-3.
- Sequentially dehydrated these slides in alcohol (70%, 85%, 95% and 100%) and air dried for an hour at room temperature.
- Denatured tissue sections at 75°C for 2 minutes and carried out BAC probe hybridization overnight in a humidified chamber at 37°C.
- Washed tissue sections in 0.5 x SSC for 5 minutes at 73°C and treated with CAS block for 10 minutes.
- Performed USP6 probe detection using FITC-anti-digoxigenin (1:500) and Alexa Fluor 594-streptavidin (1:500) (molecular probe, Eugene, OR) for 30 minutes.
- Mounted slides in Vectashield mounting medium.
- CGCG and PGCG scored positive for gene arrangement if more than 5% of cells showed splitting apart of the FISH probes.

RESULTS

Figure 1.
USP6 Breakapart Probe
Control





Figure 2.
Photomicrograph Showing
Central Giant Cell Granuloma



1) bland spindle cells, 2) reactive new bone
3) multinucleated giant cells

Figure 3. Case 1. Central Giant Cell
Granuloma Showing No Rearrangement
of USP6 Breakapart Probe




Figure 4. Case 2: Central Giant Cell
Granuloma Showing No Rearrangement
of USP6 Breakapart Probe





Figure 5.
Photomicrograph Showing
Peripheral Giant Cell Granuloma



1) bland spindle cells, 2) surface epithelium,
3) multinucleated giant cells

Figure 6. Case 3: Peripheral Giant Cell
Granuloma Showing No Rearrangement
of USP6 Breakapart Probe




Table 1. Characteristic Clinical Features of CGCG & PGCG			
	CGCG	PGCG	
Peak Prevalence	60% occur before 30 years	31-41 years	
Gender Prevalence	Females	Females	
Location	Anterior Mandible	Mandibular Gingiva	
Clinical Signs & Symptoms	Aggressive Symptomatic: Pain Rapid Growth Cortical Perforation	Non-aggressive Asymptomatic: Slow Growth Presents as red/red-blue, sessile/pedunculated nodular mass	
Radiographic Findings	Unilocular or multilocular radiolucencies with noncorticated margins	None, may see some "cupping" resorption of underlying alveolar bone	
Recurrence	15-20%	10%	

Table 2. Clinical Data of Three Patients				
Case	Location	Gender	Age (years)	Microscopic Diagnosis
1	Anterior Maxilla (Apical to #9-10)	Male	18	Central giant cell granuloma
2	Anterior Mandible (#24)	Female	37	Central giant cell granuloma
3	Anterior Mandible (Gingiva #23-24)	Female	57	Peripheral giant cell granuloma

DISCUSSION

- WHO has defined CGCG as an intraosseous lesion consisting of cellular fibrous tissue containing multiple foci of hemorrhage, aggregations of multinucleated giant cells and occasional trabeculae of woven bone.
- CGCG can present as unilocular or multilocular, radiolucent bone lesions while PGCG occurs as a gingival lesion.
- In this pilot study, recurrent CGCG and PGCG failed to demonstrate a rearrangement of USP6 genes. This lack of USP6 rearrangement suggests a reactive rather than a neoplastic pathogenesis.
- Future studies to understand the pathogenesis of these poorly understood lesions is suggested to confirm this hypothesis.

CONCLUSION

The results of this pilot study imply that CGCG and PGCG are reactive lesions with little or no neoplastic potential and may be managed conservatively.